Observational studyBreast (Edinburgh, Scotland)2026
Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practice.
Observational study in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06495164 (Palbociclib Treatment Patterns and Outcomes in HR+/HER2- MBC), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Palbociclib Treatment Patterns and Outcomes in HR+/HER2- MBC: Flatiron Database Analysis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComparative cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) effectiveness data to date are limited to real-world progression-free survival (PFS) and overall survival. Additional effectiveness measures such as time from initial treatment to progression on first subsequent therapy (rwPFS2) and real-world tumor response (rwTR) provide full understanding of CDK4/6i real-world effectiveness. This analysis compared rwPFS2 and rwTR in patients with HR+/HER2- mBC receiving first-line (1L) CDK4/6i plus an aromatase inhibitor (AI) in US routine clinical practice. PATIENTS AND
methodsP-VERIFY was a retrospective Flatiron Health Research Database analysis of adult patients with HR+/HER2- mBC who started 1L CDK4/6i (palbociclib; ribociclib; abemaciclib) plus AI between February 2015 and November 2023 (N = 9146). rwPFS2 analysis included all 9146 patients while rwTR analysis included 8010 (87.6%) patients who had ≥1 tumor response assessment. Stabilized inverse probability of treatment weighting (sIPTW) was used to balance patient baseline characteristics. A multivariable Cox proportional hazards model was used for sensitivity analysis.
resultsAfter sIPTW, no significant differences were observed across all pairwise treatment comparisons between the CDK4/6i for rwPFS2 and rwTR (all p > 0.05). Findings were generally consistent across subgroups and sensitivity analyses. Findings were also consistent in a separate analysis of patients treated from 2017 onward, corresponding with commercial availability of all three CDK4/6i in the US.
conclusionsThis real-world study demonstrated no statistically significant differences in rwPFS2 and rwTR in patients with HR+/HER2- mBC receiving 1L palbociclib, ribociclib, or abemaciclib, in combination with an AI, in routine clinical practice in the US. CLINICALTRIALS GOV IDENTIFIER: NCT06495164.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.